Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)
Launched by MERCK SHARP & DOHME LLC · Jul 25, 2008
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Treatment-naïve patients with chronic hepatitis C
- • Adults (\>18 years of age)
- • Prescribed Pegetron Redipen
- • Must meet all requirements for treatment with Pegetron Redipen
- • Must be able to obtain reimbursement of medication through private or provincial coverage
- Exclusion Criteria:
- • Active hepatitis B virus (HBV) infection (hepatitis B surface antigen \[HBsAg\] positive)
- • HIV antibody positive
- • Post liver transplant patients
- • Any other exclusion criteria as per the product Monograph
About Merck Sharp & Dohme Llc
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials